HM Capital Partners

Osteal Therapeutics Closes $23M Series C Financing

Retrieved on: 
Thursday, September 21, 2023

DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for orthopedic infections, announced today the completion of an oversubscribed $23 million Series C equity financing. The proceeds leave Osteal well-funded to submit its New Drug Application (NDA) submission to FDA and accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection (PJI).

Key Points: 
  • DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for orthopedic infections, announced today the completion of an oversubscribed $23 million Series C equity financing.
  • In conjunction with the financing, Martin Sands and Steven Sands of Asteroid Partners will join the board as board member and observer respectively.
  • Both will provide valuable insights as Osteal continues to pursue multiple growth paths.
  • Osteal is addressing this significant unmet medical need with a highly novel approach,” said Martin Sands of Asteroid Partners.

Petro Victory Energy Appoints Thomas Christian Cooper to its Board of Directors

Retrieved on: 
Thursday, June 1, 2023

DALLAS, June 1, 2023 /PRNewswire/ - Petro Victory Energy (TSXV: VRY) is pleased to announce the appointment of Thomas Christian Cooper as a new member of its Board of Directors.

Key Points: 
  • DALLAS, June 1, 2023 /PRNewswire/ - Petro Victory Energy (TSXV: VRY) is pleased to announce the appointment of Thomas Christian Cooper as a new member of its Board of Directors.
  • Mr. Cooper's extensive experience and expertise in the energy industry, particularly in energy and environmental infrastructure investments, make him a valuable addition to the board.
  • Mr. Cooper is the Founder and Managing Partner of Owl Investments, where he has successfully overseen projects and identified valuable opportunities in the energy sector.
  • Richard F. Gonzalez, CEO of Petro Victory Energy, expressed his enthusiasm regarding Mr. Cooper joining the board, stating, "We are delighted to welcome Chris Cooper as a new board member of Petro Victory Energy.

Unleashed Brands Taps 20+ Year Franchise Industry Veteran Scott Thompson as New Brand President for Premier Martial Arts

Retrieved on: 
Wednesday, April 5, 2023

DALLAS, April 5, 2023 /PRNewswire/ -- Premier Martial Arts (PMA), a franchise brand that specializes in teaching karate, krav maga, and kickboxing for children and adults has named Scott Thompson as the company's new Brand President, effective immediately. Premier Martial Arts is part of the youth enrichment platform Unleashed Brands, which is comprised of sister brands Urban Air Adventure Park, The Little Gym, Snapology, Class 101, and XP League. Premier Martial Arts joined the Unleashed Brands family in December 2021.

Key Points: 
  • DALLAS, April 5, 2023 /PRNewswire/ -- Premier Martial Arts (PMA), a franchise brand that specializes in teaching karate, krav maga, and kickboxing for children and adults has named Scott Thompson as the company's new Brand President, effective immediately.
  • Premier Martial Arts is part of the youth enrichment platform Unleashed Brands , which is comprised of sister brands Urban Air Adventure Park , The Little Gym , Snapology , Class 101 , and XP League .
  • Premier Martial Arts joined the Unleashed Brands family in December 2021.
  • "It's my continued passion to support the Premier Martial Arts culture and help our franchisees operate successful Martial Arts studios."

TriumphPay Appoints Dan Curtis as EVP, Chief Relationship Management Officer

Retrieved on: 
Monday, October 3, 2022

DALLAS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- TriumphPay, a division of TBK Bank, SSB, today announced the appointment of Dan Curtis as executive vice president, chief relationship management officer.

Key Points: 
  • DALLAS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- TriumphPay, a division of TBK Bank, SSB, today announced the appointment of Dan Curtis as executive vice president, chief relationship management officer.
  • In this role, Curtis will provide strategic leadership for TriumphPays client relationship team, as well as identify key business drivers for clients and ensure TriumphPay is meeting client demands.
  • Were incredibly excited to have Dan join our team, said Aaron P. Graft, vice chairman and chief executive officer of Triumph Bancorp, Inc. (Nasdaq: TBK).
  • Before taking over the role of president of BNSF Logistics in 2018, he served as the chief operating officer and chief financial officer for BNSF Logistics for seven years.

Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms

Retrieved on: 
Monday, August 22, 2022

SUZHOU, China, Aug. 21, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million.

Key Points: 
  • SUZHOU, China, Aug. 21, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million.
  • Focusing solely on gene and cell therapy CDMO services, Porton Advanced has rapidly established an integrated CDMO platform providing a spectrum of services covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy (MVGTs).
  • By then, Porton Advanced will have over 200,000sqft of PD, AD, and GMP manufacturing facility dedicated for gene and cell therapy.
  • Porton Advanced is a leading cell and gene therapy CDMO service provider with a very experienced, internationally oriented management and technical team.

Osteal Therapeutics Closes an Oversubscribed $30 Million Series B Financing to Advance Platform Therapy for Treatment of Musculoskeletal Infection

Retrieved on: 
Tuesday, March 8, 2022

DALLAS, March 08, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today the completion of an oversubscribed $30 million Series B equity financing. The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.

Key Points: 
  • DALLAS, March 08, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (Osteal), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today the completion of an oversubscribed $30 million Series B equity financing.
  • HM Capital led the round with full participation by existing investors Johnson and Johnson Development Corporation (JJDC) and Medvest Capital.
  • The Series B funding will be used primarily to advance Osteals lead program, VT-X7 for periprosthetic joint infection (PJI), into later-stage clinical trials.
  • Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.